Bonus BioGroup Past Earnings Performance
Past criteria checks 0/6
Bonus BioGroup's earnings have been declining at an average annual rate of -13.3%, while the Biotechs industry saw earnings growing at 11.2% annually.
Key information
-13.3%
Earnings growth rate
-6.9%
EPS growth rate
| Biotechs Industry Growth | -24.5% |
| Revenue growth rate | n/a |
| Return on equity | -97.4% |
| Net Margin | n/a |
| Last Earnings Update | 31 Dec 2023 |
Recent past performance updates
No updates
Recent updates
We're Keeping An Eye On Bonus BioGroup's (TLV:BONS) Cash Burn Rate
Apr 01
Will Bonus BioGroup (TLV:BONS) Spend Its Cash Wisely?
Dec 11We're Keeping An Eye On Bonus BioGroup's (TLV:BONS) Cash Burn Rate
Jun 14Is Bonus BioGroup (TLV:BONS) In A Good Position To Deliver On Growth Plans?
Dec 13Companies Like Bonus BioGroup (TLV:BONS) Are In A Position To Invest In Growth
Jun 26Here's Why We're Not Too Worried About Bonus BioGroup's (TLV:BONS) Cash Burn Situation
Jan 28Here's Why We're Not Too Worried About Bonus BioGroup's (TLV:BONS) Cash Burn Situation
Sep 15Here's What Bonus BioGroup Ltd.'s (TLV:BONS) Shareholder Ownership Structure Looks Like
Mar 05What Kind Of Investors Own Most Of Bonus BioGroup Ltd. (TLV:BONS)?
Nov 19Revenue & Expenses BreakdownBeta
How Bonus BioGroup makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 31 Dec 23 | 0 | -29 | 11 | 19 |
| 30 Sep 23 | 0 | -31 | 13 | 20 |
| 30 Jun 23 | 0 | -40 | 14 | 19 |
| 31 Mar 23 | 0 | -39 | 15 | 20 |
| 31 Dec 22 | 0 | -39 | 16 | 21 |
| 30 Sep 22 | 0 | -45 | 15 | 21 |
| 30 Jun 22 | 0 | -40 | 15 | 24 |
| 31 Mar 22 | 0 | -52 | 43 | 22 |
| 31 Dec 21 | 0 | -90 | 44 | 21 |
| 30 Sep 21 | 0 | -82 | 43 | 18 |
| 30 Jun 21 | 0 | -73 | 41 | 14 |
| 31 Mar 21 | 0 | -61 | 11 | 14 |
| 31 Dec 20 | 0 | -22 | 8 | 11 |
| 30 Sep 20 | 0 | -19 | 7 | 11 |
| 30 Jun 20 | 0 | -21 | 7 | 11 |
| 31 Mar 20 | 0 | -21 | 7 | 11 |
| 31 Dec 19 | 0 | -22 | 10 | 11 |
| 30 Sep 19 | 0 | -23 | 10 | 12 |
| 30 Jun 19 | 0 | -23 | 10 | 12 |
| 31 Mar 19 | 0 | -21 | 10 | 11 |
| 31 Dec 18 | 0 | -19 | 8 | 11 |
| 30 Sep 18 | 0 | -17 | 7 | 10 |
| 30 Jun 18 | 0 | -22 | 10 | 12 |
| 31 Mar 18 | 0 | -22 | 10 | 12 |
| 31 Dec 17 | 0 | -20 | 9 | 11 |
| 30 Sep 17 | 0 | -20 | 9 | 10 |
| 30 Jun 17 | 0 | -17 | 10 | 7 |
| 31 Mar 17 | 0 | -16 | 10 | 7 |
| 31 Dec 16 | 0 | -16 | 9 | 7 |
| 30 Sep 16 | 0 | -17 | 10 | 7 |
| 30 Jun 16 | 0 | -14 | 7 | 7 |
| 31 Mar 16 | 0 | -14 | 7 | 7 |
| 31 Dec 15 | 0 | -13 | 7 | 7 |
| 30 Sep 15 | 0 | -12 | 5 | 7 |
| 30 Jun 15 | 0 | -11 | 5 | 6 |
| 31 Mar 15 | 0 | -11 | 4 | 6 |
| 31 Dec 14 | 0 | -11 | 4 | 7 |
| 30 Sep 14 | 0 | -12 | 4 | 8 |
| 30 Jun 14 | 0 | -12 | 4 | 8 |
| 31 Mar 14 | 0 | -11 | 4 | 7 |
| 31 Dec 13 | 0 | -10 | 4 | 6 |
| 30 Sep 13 | 0 | -10 | 4 | 5 |
Quality Earnings: BONS is currently unprofitable.
Growing Profit Margin: BONS is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: BONS is unprofitable, and losses have increased over the past 5 years at a rate of 13.3% per year.
Accelerating Growth: Unable to compare BONS's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: BONS is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-2.3%).
Return on Equity
High ROE: BONS has a negative Return on Equity (-97.35%), as it is currently unprofitable.